JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NANDITA SINGHDesignation :- Company Secretary and Compliance Officer JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window
The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for Designated Persons and their immediate relative(s) with immediate effect i.e. January 01, 2020 till the end of 48 hours after the declaration of financial results for the Quarter ended 31st December, 2019. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosure Of Related Party Transaction Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations, (Amendments) 2018.
Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find enclosed disclosure of Related Party Transaction, in the format specified in the Accounting Standard for the half year ended September 30, 2019. This is for your information and records. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Appointment Of Additional Non-Executive Independent Director
Appointment of Additional Non-Executive Independent Director Jagsonpal Pharmaceuticals Ltd - 507789 - F=Unaudited Financial Results For The Quarter And Half Year Ended 30 September, 2019.
In terms of the provisions of Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Un-Audited Financial Results for the Quarter and Half Year ended 30th September, 2019 duly approved by the Board at its meeting held on 14th November, 2019. The Limited Review Report on the Un-Audited Financial Results for the Quarter and Half Year ended 30th September, 2019 in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015 is also enclosed herewith. Jagsonpal Pharmaceuticals Ltd - 507789 - Outcome Of Board Meeting
We wish to inform you that the Board of Directors of the Company at their meeting held today, (i.e. Thursday, the 14th Day of November, 2019), have inter alia, approved and taken on record the followings: 1. Un-Audited Financial Results of the Company for the Quarter and Half Year ended 30th September, 2019; 2. Limited Review Report for the Quarter and Half Year ended 30th September, 2019; 3. Appointment of Mr. Ashok Kumar Pati and Mr. Mammen Mathew as the Additional Non-Executive Independent Director on the Board w.e.f. 14th Day of November, 2019. 4. Took note of Appointment of Ms. Nandita Singh as the Company Secretary and Compliance Officer of the Company. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2019.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2019 ,inter alia, to consider and approve 1. The Un-Audited Financial Results along with Statement of Assets & Liabilities and Cash Flow Statement of the company for the quarter and half year ended 30th September, 2019; 2. To consider and take note of Limited Review Report on Un-Audited Financial Results of the company for the quarter and half year ended 30th September, 2019; 3. Other agenda items as placed before the Board. Jagsonpal Pharmaceuticals Ltd - 507789 - CERTIFICATE UNDER SUB - REGULATION 9 & 10 REGULATION 40 OF THE SEBI (LISTING OBLIGATIONS & DISCLOSURE REQUIREMENT) REGULATIONS, 2015 FOR THE HALF YEAR ENDED ON 30 SEPTEMBER, 2019.
SUBMISSION OF CERTIFICATE UNDER SUB - REGULATION 9 & 10 REGULATION 40 OF THE SEBI (LISTING OBLIGATIONS & DISCLOSURE REQUIREMENT) REGULATIONS, 2015 FOR THE HALF YEAR ENDED ON 30 SEPTEMBER, 2019. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliance Certificate For The Period Ended 30-09-2019.
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the compliance certificate, for the half year ended on 30th September, 2019, signed by compliance officer of the company and the Authorized representative of Share Transfer Agent.